- Novo Nordisk is investing 550 million DKK in a new R&D facility in Bagsværd, Denmark.
- The plant will be operational by late 2016 and run by CMC Supply.
- It will produce active pharmaceutical ingredients for diabetes drugs.
- The facility includes one purification line and can be expanded.
Investment and Purpose
Novo Nordisk is investing 550 million Danish kroner (100 million US dollars) in a new research and development facility in Bagsværd, Denmark. The new purification plant will expand the company’s capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs under development.
Operational Timeline
The pilot plant is expected to be fully operational by late 2016. It will be managed by CMC Supply, a unit within Novo Nordisk R&D responsible for developing, producing, and formulating new protein and peptide processes.
Job Creation
The new facility will create up to 35 new jobs over a two-year period. This is in addition to the 100 new employees CMC Supply plans to hire in Denmark in 2014.
Facility Details
The project involves the establishment of a pilot plant with one purification line, with the potential to double its size to further increase capacity. The facility will cover a total area of 2,700 square meters and will include 5 kilometers of steel pipes.
